The Biden administration announced support for waiving intellectual property protections for COVID-19 vaccines. Several developing countries have advocated for the move, saying it would allow them to produce their own generic vaccines to boost inoculations. (The Washington Post)

Former Merck head Roger Perlmutter announced he will serve as CEO of a startup using microscope technology to help develop new medicines. Eikon Therapeutics has raised $148 million to examine how the microscopes could “make movies” of what’s happening inside cells. (STAT)

German company CureVac is close to announcing results from the late-stage clinical trial on its COVID-19 vaccine. If the results are positive, the vaccine could help assuage worldwide demand. (The New York Times)

Eli Lilly employees have accused a factory executive of altering documents to hide serious quality issues at a U.S. plant producing COVID-19 treatments. The plant has been under investigation by the Food and Drug Administration. (Reuters)

Athenex will spend $70 million to acquire Kuur Therapeutics. The acquisition comes several weeks after Athenex received a CRL for its oral chemotherapy candidate. (Endpoints News)